Navigation Links
Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
Date:3/24/2009

ensive care units and other hospital settings.

"Since 2003, AACE and the ADA have worked together to provide recommendations for treatment of inpatient hyperglycemia, and these efforts have contributed to a growing national movement viewing the management of hyperglycemia in hospitals as a quality care measure," Dr. Etie S. Moghissi, AACE Chair of Inpatient Glycemic Control Task Force said.

Recognizing the critical importance of controlling hyperglycemic states in conjunction with the results of recent randomized trials such as NICE-SUGAR, the two organizations recently convened a Consensus Panel to extensively review the most current literature and up-to-date recommendations for treatment of hyperglycemia in the hospital.

"The central goal of the ADA/AACE inpatient task force is to identify reasonable, achievable, and safe glucose targets, and to describe the protocols, procedures, and system improvements needed to achieve inpatient optimal glucose control efficiently and safely," Dr. Mary Korytkowski, ADA Chair of Inpatient Glycemic Control Task Force said.

Complete recommendations from the panel will be published in Endocrine Practice and Diabetes Care later in the spring. Until more information is available, it seems reasonable for clinicians to treat critical care patients with the less intensive - yet good - glucose control strategies used in the conventional arm of the NICE-SUGAR trial.

About The NICE-SUGAR Study

Hyperglycemia in the hospital, whether it occurs in patients with known diabetes or is temporarily stress-induced, has long been known to be associated with poor outcomes such as longer length of stay, increased rates of infection, and in-hospital death. Observational studies and early randomized trials have suggested that lowering glucose levels can improve outcomes, especially in critical care patients treated with
'/>"/>

SOURCE American Association of Clinical Endocrinologists; American Diabetes Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. A Joint Statement From Americas Prostate Cancer Advocacy, Education, and Support Organizations
2. Octogenarians: Not Too Old for Joint Replacement
3. Beating Blood Clots after Joint Replacement
4. When to Have That Joint Replacement?
5. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
6. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
7. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
10. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
11. Joint Commission Urges Patients to Speak Up About Pain

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...,Nov.23/PRNewswire/--LightSciencesOncology,Inc.(LS...oftheBoard,Elekta,toanewlycreatedseatonitsboardofd...medical-productcompanies,includingElekta,tomarketl...gsadditionalstrengthinbusinessdevelopmenttotheboar...ighisaworldleaderincancer-therapybusinessdevelopme...
(Date:11/23/2009)....,Nov.23/PRNewswire-FirstCall/-- CumberlandPharmac...p-lineresultsfromastudyevaluatingthesafetyandeffic...inhospitalizedburnpatients. ,, Statisticalsigni...everinburnpatientsoverthefirst24hoursoftreatment.T...rddegreeburnscoveringmorethan10percenttotalbodysur...
(Date:11/23/2009)...s,Nov.23/PRNewswire-FirstCall/--WoundManagementTec...ingproviderofspecialtymedicalproducts,announcedtha...comprehensivemanagementbusinessupdatetoillustratet...2009salesincreased33.5%to$102,926vs.Q32008salesof$...asedto$3,327,892vs.Q32008shareholderequityof$(321,...
Breaking Medicine Technology:Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Futronic Windows 7 Biometric Framework Driver is Signed by Microsoft 10364 1Futronic Windows 7 Biometric Framework Driver is Signed by Microsoft 10364 2WarrantyElephant Launches 26quot 3BMediElephant 26quot 3B a New Medication Reminder Service Inspired by WarrantyElephant User Rhonda Lewis Founder o 59503 1WarrantyElephant Launches 26quot 3BMediElephant 26quot 3B a New Medication Reminder Service Inspired by WarrantyElephant User Rhonda Lewis Founder o 59503 2You Me and Tea is Pleased to Announce the Website Debut of youmeandtea com 59498 1You Me and Tea is Pleased to Announce the Website Debut of youmeandtea com 59498 2
..., Calif., June 2 ,Bayer HealthCare Pharmaceuticals...XX ) today announced the presentation of new clini...elopment program for Nexavar(R),(sorafenib) tablet...gastric and ovarian cancers. Nexavar is currently ...nt of patients with unresectable liver cancer and,...
...edarex, Inc.,(Nasdaq: MEDX ) today announced prel...1106 (ONO-4538: development code of Ono Pharmaceut...Data presented from patients with,recurrent or tre... safety,tolerability and pharmacokinetic profile o...vidence of anti-tumor activity was observed,includ...
Other Medicine Technology:New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting 2New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting 3New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting 4New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting 5New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting 6Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/--Howistheeconomyaff...tchi&SaatchiWellnessonWellness&theEconomy,...cusshiftsfromahealthylifestyleofexerciseanddiettoo...micclimate. ,, Thesurvey,smostdramaticfindingwa...iftedfromatraditionalfocusonhealthandwellbeingtoto...
(Date:11/23/2009)...vember 23, 2009 -- Exposure shortly after birth to...stion and particles from diesel emissions are asso...ty children, according to a new study by researche...ntal Health (CCCEH) at Columbia University,s Mailm...t to analyze the effects of exposure to airborne m...
(Date:11/23/2009)... Plastic and Reconstructive S...ned to keep you updated on the most current journa...ns. To obtain any of the full studies highlighted ...on, please contact ASPS Public Relations at (847) ... (Vocus) November 23, 2009 -- Yes, P...
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/-- ,, Reportlinke...bleinitscatalogue. ,, http://www.reportlinker...--A-Guide-to-Markets-Products-and-Innovation-2nd-E...r&utm_campaign=prnewswire ,, Despitethegr...n,childrenremainasignificantconsumergroupthatcanno...
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/--Reportlinker.coman...scatalogue. ,, HandSanitizers-USMarketTrends ...Sanitizers---US-Market-Trends.html#utm_source=prne...re ,, Globalthreatsinthepast,suchasSARS,out...need,andimportanceofhandhygieneinpreventingthespre...
Breaking Medicine News(10 mins):Health News:Being Well Is About Reinvention - Not Health 2Health News:Being Well Is About Reinvention - Not Health 3Health News:Exposures to metals and diesel emissions in air linked to respiratory symptoms in children 2Health News:Plastic and Reconstructive Surgery...In Brief 2Health News:Plastic and Reconstructive Surgery...In Brief 3Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 2Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 3Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 4Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 5Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 6Health News:Reportlinker Adds Children's Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition 7Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 2Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 3Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 4
...ADELPHIA Researchers from the University of Penns...ect of a protein deficiency, which is the basis of... (SMA), is not restricted to motor nerve cells, su..., PhD, the Isaac Norris Professor of Biochemistry ...
...E, Bermuda, May 29 PartnerRe Ltd.,(NYSE: PRE ) t...hief,Financial Officer Albert Benchimol is schedul...ia Waller conference on "The Credit Markets,Crisis...008 from 9 a.m. - 2 p.m. local time in England., ...
...K, May 29 HMS Holdings Corp. (Nasdaq:,HMSY) today...08 Spring,Investment Conference, which will be hel...alter Hosp, Chief Financial Officer of HMS Holding...ation of benefits, and program integrity services ...
...embers of the Women,s Dermatologic Society (WDS) c...outreach to LPGA Tour players, caddies, fans, and...lifton, New Jersey, CLIFTON, N.J., May 29 To pro...dermatologists,representing the Women,s Dermatolog...
...ee-year agreement extends alliance members, access...on-invasive temperature therapy ...oit Medical Systems, Inc.,today announced its awar...ankets, localized heat therapy and cold,therapy sy...
... Percent of Families Participating in Outdoor Acti... Protected, Your Beauty Routine Uninterrup...INE, Wis., May 29 Americans sure do know how to m... percent), watch fireworks (59 percent), attend ou...
Other Medicine News:Health News:Penn researchers gain new insights on spinal muscular atrophy 2Health News:PartnerRe Executive Vice President & Chief Financial Officer Albert Benchimol to Present at the FPK CCW Credit Risk Conference in London on June 6, 2008 2Health News:New Jersey Dermatologist Volunteers Show Golf Enthusiasts How to Play Safe in the Sun 2Health News:New Jersey Dermatologist Volunteers Show Golf Enthusiasts How to Play Safe in the Sun 3Health News:Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems 2Health News:Keep Your Cool and Sanity This Summer! 2Health News:Keep Your Cool and Sanity This Summer! 3Health News:Keep Your Cool and Sanity This Summer! 4Health News:Keep Your Cool and Sanity This Summer! 5
Renu Multiplus Lubricating and Rewetting Drops
Sensitive Eyes Saline/Cleaning Solution
Sensitive Eyes Plus Saline Solution
Renu 1-Step Enzymatic Cleaner
Medicine Products: